PolyTherics acquires Warwick Effect Polymers and expands technology portfolio to enable the development of better biopharmaceuticals
PolyTherics Limited announced the acquisition of Warwick Effect Polymers (“WEP”), a provider of specialty biopolymers for the modification of biological products.
WEP has developed two proprietary biopolymer technologies, PolyPEG® and GlycoPol®, both of which are based on the leading academic work of Professor David Haddleton of the University of Warwick utilising Living Radical Polymerisation. WEP has agreements with several global pharmaceutical and biotechnology companies for the evaluation of PolyPEG® or GlycoPol® and the company expects to announce licensing deals for these technologies this year.
“With this acquisition of WEP, PolyTherics now has broader technology capabilities for the pharmaceutical and biotechnology company partners that the two companies have separately served,” commented John Burt, CEO of PolyTherics. “This acquisition enables the combined businesses to provide a portfolio of best-in-class technologies to enable better biopharmaceuticals which will benefit patients.”
Other news from the department business & finance
